ASH 2018: Key takeaways

 
Conference Edition | Dec.​ 5,​ 2018
 
 

Beat AML® Master Trial

 

See how Syneos Health is helping the Leukemia & Lymphoma Society expedite development of innovative therapies for AML Patients.

Learn more >>

Advertisement
 
Brought to you by logo
 
 

Editor's Note


 
 

There's nothing like an American Society of Hematology event to get the blood pumping, and this year's annual meeting was no exception.


Some key takeaways: First generation CAR-T therapies demonstrated lasting efficacy for some, while a newer wave offered impressive responses in hard-to-treat cancers. Durability will be a focus with these therapies moving forward, and a potential differentiator as the market matures.


Competition may also come from bispecifics and antibody drug conjugates, two increasingly popular areas of cancer drug development. At least in the near-term, however, experts see places at the table for a variety of treatment options.


And on a larger scale, reimbursement and clinical trial design will continue to factor into how the blood disorder space evolves.


We hope you enjoy this collection of our biggest stories from ASH. Of course, we'd love to hear from you too. Please share any thoughts or feedback via email. Thanks for reading!


Jacob Bell
Reporter, BioPharma Dive
E-mail
 
 
overheard bubble
 

Overheard at the show

 
"Every one of today's therapies for malignant hematological disease is available because of a successful clinical trial, but we need to bring these trials up-to-date ... Improving clinical trial design will help prioritize good drugs for more testing."
 
– Ned Sharpless, Director of the National Cancer Institute
 

Event coverage


 
 

 

 

 

 

 

 

 

 
 
overheard bubble
 

Parting thought

 
At ASH, we focused on news critical to companies we cover regularly. Just as important, though, is research that extends beyond the bounds of industry, such as a study finding hydroxyurea feasible and safe for children in sub-Saharan Africa or a test of how well machine learning can predict the prognosis for patients with myelodysplastic syndromes.